JPMorgan Chase & Co. increased its holdings in shares of Theravance Biopharma, Inc. (NASDAQ:TBPH – Free Report) by 2.9% in the third quarter, according to its most recent filing with the SEC. The fund owned 266,879 shares of the biopharmaceutical company’s stock after acquiring an additional 7,620 shares during the period. JPMorgan Chase & Co. owned about 0.54% of Theravance Biopharma worth $2,151,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also recently modified their holdings of the business. Barclays PLC lifted its stake in shares of Theravance Biopharma by 279.9% during the 3rd quarter. Barclays PLC now owns 65,580 shares of the biopharmaceutical company’s stock worth $529,000 after acquiring an additional 48,316 shares during the last quarter. Y Intercept Hong Kong Ltd bought a new stake in shares of Theravance Biopharma during the 3rd quarter worth approximately $251,000. XTX Topco Ltd lifted its stake in shares of Theravance Biopharma by 34.5% during the 3rd quarter. XTX Topco Ltd now owns 20,439 shares of the biopharmaceutical company’s stock worth $165,000 after acquiring an additional 5,243 shares during the last quarter. Jane Street Group LLC lifted its stake in shares of Theravance Biopharma by 1.1% during the 3rd quarter. Jane Street Group LLC now owns 144,575 shares of the biopharmaceutical company’s stock worth $1,165,000 after acquiring an additional 1,640 shares during the last quarter. Finally, PDT Partners LLC lifted its stake in shares of Theravance Biopharma by 31.2% during the 3rd quarter. PDT Partners LLC now owns 87,177 shares of the biopharmaceutical company’s stock worth $703,000 after acquiring an additional 20,738 shares during the last quarter. 99.10% of the stock is owned by institutional investors.
Theravance Biopharma Stock Up 6.6 %
Shares of NASDAQ TBPH opened at $9.15 on Wednesday. The business has a fifty day simple moving average of $9.45 and a two-hundred day simple moving average of $8.90. The firm has a market cap of $449.91 million, a PE ratio of -9.06 and a beta of 0.21. Theravance Biopharma, Inc. has a twelve month low of $7.44 and a twelve month high of $10.44.
Insider Buying and Selling at Theravance Biopharma
In other news, SVP Rhonda Farnum sold 4,000 shares of the business’s stock in a transaction on Monday, November 11th. The stock was sold at an average price of $9.00, for a total value of $36,000.00. Following the completion of the transaction, the senior vice president now directly owns 322,743 shares of the company’s stock, valued at approximately $2,904,687. The trade was a 1.22 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 6.90% of the stock is currently owned by corporate insiders.
About Theravance Biopharma
Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.
See Also
- Five stocks we like better than Theravance Biopharma
- What is the Shanghai Stock Exchange Composite Index?
- SAP’s Strong Momentum: A Bullish Setup for Investors
- Trading Halts Explained
- BlackRock Breaks Records: Why the Stock Still Has Room to Run
- Insider Selling Explained: Can it Inform Your Investing Choices?
- Duke vs. NRG: Which Energy Stock Will Power Higher Gains?
Want to see what other hedge funds are holding TBPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Theravance Biopharma, Inc. (NASDAQ:TBPH – Free Report).
Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.